Abstract 132P
Background
There is an unmet need to improve neoadjuvant chemotherapy (NAC) to decrease postoperative residual disease (R0 rate: 50%) and improve prognosis in ovarian cancer (OC). R0 rate and histopathological response of interval cytoreductive surgery (IDS) after NAC combined with immune checkpoint inhibitors were reported to be encouraging. Cadonilimab (AK104) is a tetravalent bispecific antibody targeting PD-1 and CTLA-4. In this study, we report the efficacy and safety of AK104 with NAC in patients with advanced-stage ovarian cancer (NCT05430906).
Methods
This study is an open-label, prospective, single arm, phase II study of evaluating the efficacy and safety of cadonilimab combined with chemotherapy as neoadjuvant treatment for advanced ovarian cancer. Patients received neoadjuvant therapy of cadonilimab plus platinum-taxane chemotherapy (3 to 4 cycles) followed by surgery. The primary endpoint was the R0 rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR), chemotherapy response score (CRS), pathologic complete response (pCR), progression-free survival (PFS), and safety.
Results
28 patients were enrolled from Dec 12, 2022, to Sep 12, 2024. The median patient age was 54 years (range 45–70 years), and most patients presented with high-grade serous carcinoma (96.4%) and FIGO stage IVa(14.3%), IVb disease (67.9%). 23 (82.1%) patients had undergone IDS with an R0 resection rate of 78.3%. ORR was 92.3%, including 7.7% CR and 84.6% PR. 21.7% achieved pCR, and 13.0% had a CRS of 3. The median PFS was 17.3 months. Overall survival data remained immature as of the cut-off date. Treatment-related AEs (TRAEs) of any grade occurred in 15 (53.6%) patients. Grade ≥3 TRAEs occurred in 3 (10.7%) patients. Grade ≥ 3 irAE (immune⁃mediated colitis) occurred in 1 (3.6%) patient. All of the TRAEs, including severe AEs, were manageable, with no new safety concerns in this study.
Conclusions
This study showed promising activity with a durable clinical response, supporting the potential of NAC with cadonilimab in advanced-stage ovarian cancer. Meanwhile, long-term overall survival data require ongoing assessment.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract